Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 4 of 4 for “"Hypomethylating agents"”.

  1. Role of RIP3 in DNA damaging agent-induced breast cancer cell death

    … is activated in response to chemotherapeutic agents and contributes to chemotherapy-induced breast cancer cell death. However, we also show that RIP3 expression is silenced in basal like breast cancer cell lines due to DNA methylation near its transcription start site. Due to this silencing …

    ajou Repository record for Role of RIP3 in DNA damaging agent-induced breast cancer cell death (opens in a new tab)

  2. Investigating the molecular dynamics of gene re-silencing following treatment with epigenetic therapies

    … gene (TSG) inactivation in cancer. DNA hypomethylating agents such as 5-Aza-2’deoxycytidine (5-Aza-dC) are approved for the treatment of myelodysplastic syndrome and show promise in the treatment of solid tumours. These therapies are thought to exert their anti-tumour effects by …

    unsw Repository record for Investigating the molecular dynamics of gene re-silencing following treatment with epigenetic therapies (opens in a new tab)

  3. Single Cell Proteogenomics Analysis of AML Samples Treated with Decitabine and Venetoclax Reveals Divergent Treatment Escape Mechanisms

    … Since its approval, the combination therapy of hypomethylating agents and Venetoclax (HMA+Ven) has become a standard of care for acute myeloid leukemia (AML) patients unfit for intensive chemotherapy. Nonetheless, clinical challenges persist as patients either do not respond or eventually …

    uthsc Repository record for Single Cell Proteogenomics Analysis of AML Samples Treated with Decitabine and Venetoclax Reveals Divergent Treatment Escape Mechanisms (opens in a new tab)

  4. PATTERN OF INNATE IMMUNITY IN PATIENTS AFFECTED BY MYELODYSPLASTIC SYNDROME (MDS) EITHER BEFORE ANDAFTER HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)

    … therapies, mainly based on the use of hypomethylating agents (HMAs), are not curative and the current patient risk stratification, aimed at identifying MDS patients with a higher risk to progress to AML, ineffectively predicts patient prognosis and response to therapies. Moreover, the …

    milano Repository record for PATTERN OF INNATE IMMUNITY IN PATIENTS AFFECTED BY MYELODYSPLASTIC SYNDROME (MDS) EITHER BEFORE ANDAFTER HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) (opens in a new tab)